These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 11781624

  • 41. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W, Cooperative German Transplant Study Group.
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [Abstract] [Full Text] [Related]

  • 42. Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens.
    Omazic B, Hentschke P, Näsman-Björk I, Mattsson J, Oxelius VA, Ringdén O, Barkholt L, Permert J, Lundkvist I.
    Scand J Immunol; 2005 Jan; 61(1):72-81. PubMed ID: 15644125
    [Abstract] [Full Text] [Related]

  • 43. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M.
    Dtsch Med Wochenschr; 2005 Sep 23; 130(38):2125-9. PubMed ID: 16172951
    [Abstract] [Full Text] [Related]

  • 44. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, Ullmann AJ, Huber C, Kolbe K, Herr W.
    Ann Hematol; 2005 May 23; 84(5):331-8. PubMed ID: 15726363
    [Abstract] [Full Text] [Related]

  • 45. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R, Rondelli D.
    Bone Marrow Transplant; 2006 Oct 23; 38(7):477-82. PubMed ID: 16980995
    [Abstract] [Full Text] [Related]

  • 46. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M, Bagattini S, Chabannon C, Faucher C, Bardou VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D.
    Exp Hematol; 2004 Nov 23; 32(11):1097-102. PubMed ID: 15539088
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.
    Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Maraninchi D, Bardou VJ, Blaise D.
    Transfusion; 2004 Apr 23; 44(4):501-8. PubMed ID: 15043564
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
    Hussein AA, Al-Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel-Rahman F, Abu-Jazar H, Sharma S, Najjar R, Frangoul H.
    Pediatr Blood Cancer; 2013 Aug 23; 60(8):1345-9. PubMed ID: 23424175
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Chantepie SP, Gac AC, Reman O.
    Leuk Res; 2014 May 23; 38(5):569-74. PubMed ID: 24655805
    [Abstract] [Full Text] [Related]

  • 58. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
    Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito YM, Tanaka J, Koike T, Asaka M, Imamura M.
    Am J Hematol; 2010 Apr 23; 85(4):243-8. PubMed ID: 20162540
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
    Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA.
    Bone Marrow Transplant; 2011 Jan 23; 46(1):84-9. PubMed ID: 20305699
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.